Skip to main content
. 2022 Apr 8;5(4):e226567. doi: 10.1001/jamanetworkopen.2022.6567

Figure 1. Risk of Alzheimer Disease and Related Dementia in Patients Treated With Tofacitinib, Tocilizumab, or Tumor Necrosis Factor Inhibitors (TNFi) vs Abatacept After 1:1 Propensity Score Matching, Medicare Data 2007-2017.

Figure 1.

Analysis 1 indicates an as-treated follow-up approach; analysis 2, an as-started follow-up approach incorporating a 6-month induction period; analysis 3, incorporating a 6-month symptom to diagnosis period; analysis 4, alternate outcome definition; and HR, hazard ratio.